Patents by Inventor Joaquin Madrenas

Joaquin Madrenas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Using undifferentiated embryonic stem cells to control the immune system
    Patent number: 7799324
    Abstract: This disclosure provides a system for minimizing the alloreactivity of tissue transplants. The patient is administered with undifferentiated embryonic stem cells or early progenitor cells. This induces a state of inflammatory quiescence or immune unresponsiveness, which in turn enhances engraftment of cells derived from the same stem cell line given for purposes of regenerative medicine.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: September 21, 2010
    Assignees: Geron Corporation, University of Western Ontario
    Inventors: Mickie Bhatia, Joaquin Madrenas, Iris A. Ferber, Anish Sen Majumdar
  • Using undifferentiated embryonic stem cells to control the immune system
    Publication number: 20050282272
    Abstract: This disclosure provides a system for minimizing the alloreactivity of tissue transplants. The patient is administered with undifferentiated embryonic stem cells or early progenitor cells. This induces a state of inflammatory quiescence or immune unresponsiveness, which in turn enhances engraftment of cells derived from the same stem cell line given for purposes of regenerative medicine.
    Type: Application
    Filed: September 24, 2004
    Publication date: December 22, 2005
    Applicants: The Robarts Research Institute, Geron Corporation
    Inventors: Mickie Bhatia, Joaquin Madrenas, Iris Ferber, Anish Majumdar
  • Methods for modulating an immune response by modulating the interaction between CTLA4 and PP2A
    Publication number: 20030166531
    Abstract: The present invention provides methods for modulating an immune response comprising contacting a cell with an agent that modulates the interaction between CTLA4 and PP2AA via modulating the lysine rich motif of CTLA4. The invention further provides methods for treating a subject having a disorder that would benefit from down regulation of an immune response comprising administering an agent that modulates the interaction between CTLA4 and PP2AA via modulating the lysine rich motif of CTLA4. The invention also provides methods for identifying compounds capable of modulating the interaction of CTLA4 and PP2AA.
    Type: Application
    Filed: February 15, 2002
    Publication date: September 4, 2003
    Applicant: Genetics Institute, Inc.
    Inventors: Joaquin Madrenas, Mary Collins, Beatriz Carreno, Vijay Kuchroo
  • Methods for modulating an immune response by modulating the interaction between CTLA4 and PP2A
    Publication number: 20030004113
    Abstract: The present invention provides methods for modulating an immune response comprising contacting a cell with an agent that modulates the interaction between CTLA4 and PP2AA via modulating the lysine rich motif of CTLA4. The invention further provides methods for treating a subject having a disorder that would benefit from down regulation of an immune response comprising administering an agent that modulates the interaction between CTLA4 and PP2AA via modulating the lysine rich motif of CTLA4. The invention also provides methods for identifying compounds capable of modulating the interaction of CTLA4 and PP2AA.
    Type: Application
    Filed: August 2, 2002
    Publication date: January 2, 2003
    Inventors: Joaquin Madrenas, Mary Collins, Beatriz Carreno